BWXT Q3 Revenue Up 10%, EPS Up 26%, 2026 Guidance Tightened
BWXT is trading near its 52-week low of $123.05 (6.0% above the low).
Summary
BWXT beat its own prior-year marks across the board in Q3 2026: revenue rose 10% to $953.0M, with Commercial Operations up 25% to $314.2M on commercial nuclear components, services and medical. EPS came in at $1.11 and net income at $101.7M, while non-GAAP EPS came in at $1.26 versus $1.00 a year ago and adjusted EBITDA climbed 19% to $179.7M. Free cash flow was the standout at $150.5M, up 59%, on stronger net income and better working capital. Management reaffirmed ~$3,800M 2026 revenue and tightened non-GAAP EPS to $4.72-$4.77 (from $4.70-$4.80), adjusted EBITDA to ~$667M and free cash flow to $350-$360M. CEO Geveden also gave a preliminary 2027 outlook for high-single-digit revenue growth and high-single-digit to low-double-digit adjusted EBITDA and non-GAAP EPS growth, framing the company as early in a multi-decadal nuclear investment cycle. This follows the $189M naval reactor fuel contract announced October 1st, which supports the Government Operations backlog. The earnings call is scheduled for 5:00 p.m. EST today.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — BWXT introduced a preliminary 2027 outlook for high-single-digit revenue growth and high-single-digit to low-double-digit adjusted EBITDA and non-GAAP EPS growth.
At the time of this announcement, BWXT was trading at $130.47 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $12B. The 52-week trading range was $123.05 to $241.82. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.